PARP means poly (adenosine diphosphate [ADP] -ribose) polymerase. It is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain (the PAR chain) and transfers them to the target proteins. This helps to restore DNA when it is damaged. DNA can be damaged by many factors, including exposure to UV rays, radiation, some anti-cancer drugs or other substances in the environment. PARP inhibitors block an enzyme critical to the repair of single stranded breaks in DNA. Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency in other DNA repair pathways.
The U.S. is the major market of PARP inhibitor supported by PARPi for ovarian cancer in the market. The U.S. region is likely to experience further growth of PARP inhibitor market with upcoming PARP inhibitors and growing cases of cancer.
The global PARP (Poly ADP-Ribose Polymerase) Inhibitor market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the PARP (Poly ADP-Ribose Polymerase) Inhibitor market based on company, product type, end user and key regions.
This report studies the global market size of PARP (Poly ADP-Ribose Polymerase) Inhibitor in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of PARP (Poly ADP-Ribose Polymerase) Inhibitor in these regions.
This research report categorizes the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market by top players/brands, region, type and end user. This report also studies the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Market size by Product
Market size by End User
Market size by Region
Central & South America
Rest of Central & South America
Middle East & Africa
The study objectives of this report are:
To study and analyze the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of PARP (Poly ADP-Ribose Polymerase) Inhibitor market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global PARP (Poly ADP-Ribose Polymerase) Inhibitor companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of PARP (Poly ADP-Ribose Polymerase) Inhibitor submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of PARP (Poly ADP-Ribose Polymerase) Inhibitor are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of PARP (Poly ADP-Ribose Polymerase) Inhibitor market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.